NasdaqGS - Delayed Quote USD

Taysha Gene Therapies, Inc. (TSHA)

2.7100
-0.0400
(-1.45%)
At close: May 30 at 4:00:01 PM EDT
2.6800
-0.03
(-1.11%)
After hours: May 30 at 7:48:03 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
7,224
8,333
15,451
2,502
0
Operating Expense
90,936
94,954
86,825
128,529
173,267
Operating Income
-83,712
-86,621
-71,374
-126,027
-173,267
Net Non Operating Interest Income Expense
6,481
6,838
-1,426
-3,549
-1,256
Other Income Expense
-9,535
-9,515
-38,766
-36,438
--
Pretax Income
-86,766
-89,298
-111,566
-166,014
-174,523
Net Income Common Stockholders
-86,766
-89,298
-111,566
-166,014
-174,523
Diluted NI Available to Com Stockholders
-86,766
-89,298
-111,566
-166,014
-174,523
Basic EPS
-0.34
--
-0.96
-3.78
-4.64
Diluted EPS
-0.34
--
-0.96
-3.78
-4.64
Basic Average Shares
259,648.6680
--
116,121.4820
43,952.0150
37,650.5660
Diluted Average Shares
259,648.6680
--
116,121.4820
43,952.0150
37,650.5660
Total Operating Income as Reported
-88,550
-91,459
-72,439
-162,447
-173,267
Total Expenses
90,936
94,954
86,825
128,529
173,267
Net Income from Continuing & Discontinued Operation
-86,766
-89,298
-111,566
-166,014
-174,523
Normalized Income
-82,383
-84,476
-74,385
-129,594
-174,523
Interest Income
6,573
6,940
3,572
249
172
Interest Expense
92
102
4,998
3,798
1,428
Net Interest Income
6,481
6,838
-1,426
-3,549
-1,256
EBIT
-86,674
-89,196
-106,568
-162,216
-173,095
EBITDA
-85,471
-87,951
-105,197
-161,044
-172,603
Reconciled Depreciation
1,203
1,245
1,371
1,172
492
Net Income from Continuing Operation Net Minority Interest
-86,766
-89,298
-111,566
-166,014
-174,523
Total Unusual Items Excluding Goodwill
-4,383
-4,822
-37,181
-36,420
0
Total Unusual Items
-4,383
-4,822
-37,181
-36,420
0
Normalized EBITDA
-81,088
-83,129
-68,016
-124,624
-172,603
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 9/24/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ORIC ORIC Pharmaceuticals, Inc.
8.17
+2.51%
 
LXEO Lexeo Therapeutics, Inc.
2.7200
-5.23%
 
ITOS iTeos Therapeutics, Inc.
10.02
-0.10%
 
RCKT Rocket Pharmaceuticals, Inc.
2.5100
-4.20%
 
PRTA Prothena Corporation plc
4.5900
-2.34%
 
NGNE Neurogene Inc.
17.01
-9.23%
 
TNGX Tango Therapeutics, Inc.
2.2200
-4.72%
 
SVRA Savara Inc.
2.2800
+1.79%
 
IFRX InflaRx N.V.
0.8025
-5.60%
 
CTMX CytomX Therapeutics, Inc.
2.6500
+5.16%